Abstract
To the Editor: Regarding the report by Fakih et al. (Dec. 7 issue)1 on the CodeBreaK 300 trial of sotorasib in KRAS-mutated colorectal cancer: examination of the data finds problems similar to those identified by the Food and Drug Administration in the CodeBreaK 200 trial of sotorasib in non–small-cell lung cancer.2 The progression-free survival analysis suffers from asymmetric censoring that can disrupt randomization balance if patients who dropped out are predominantly in one trial group. In the first 2 months, data from 11 of 54 patients (20%) assigned to the standard-care group were censored, as compared with 2 patients in .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
